Lazard Asset Management’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-879
Closed -$27K 2172
2023
Q4
$27K Sell
879
-1,097
-56% -$34.4K ﹤0.01% 2026
2023
Q3
$69K Hold
1,976
﹤0.01% 1761
2023
Q2
$74K Buy
1,976
+234
+13% +$9.33K ﹤0.01% 1693
2023
Q1
$64K Hold
1,742
﹤0.01% 1710
2022
Q4
$72K Sell
1,742
-74
-4% -$3.05K ﹤0.01% 1651
2022
Q3
$56K Buy
1,816
+651
+56% +$22.9K ﹤0.01% 1752
2022
Q2
$36K Sell
1,165
-508
-30% -$16.5K ﹤0.01% 1946
2022
Q1
$59K Buy
1,673
+207
+14% +$7.1K ﹤0.01% 1659
2021
Q4
$56K Buy
1,466
+196
+15% +$8.17K ﹤0.01% 1688
2021
Q3
$54K Buy
1,270
+145
+13% +$6.51K ﹤0.01% 1650
2021
Q2
$45K Buy
1,125
+202
+22% +$7.79K ﹤0.01% 1634
2021
Q1
$30K Sell
923
-83
-8% -$3.12K ﹤0.01% 1645
2020
Q4
$40K Sell
1,006
-167
-14% -$6.24K ﹤0.01% 1462
2020
Q3
$42K Sell
1,173
-243
-17% -$8.79K ﹤0.01% 1233
2020
Q2
$47K Sell
1,416
-1,652,241
-100% -$45M ﹤0.01% 1242
2020
Q1
$35M Sell
1,653,657
-26,380
-2% -$588K 0.06% 205
2019
Q4
$37.5M Sell
1,680,037
-14,084
-0.8% -$307K 0.05% 226
2019
Q3
$34.3M Buy
+1,694,121
New +$33.4M 0.06% 233

Other funds holding GMAB

Lazard Asset Management's GMAB Position: Q1 2024 in Review

Lazard Asset Management sold out of Genmab (GMAB) in Q1 2024, closing a stake of 879 shares — an estimated $27K sold.

Lazard Asset Management first reported a position in GMAB in Q3 2019 and held it in 18 quarters. The position peaked at $37.5M in Q4 2019. 227 funds tracked by Wall St. Rank hold GMAB as of Q1 2024.

  • Lazard Asset Management reported no remaining Genmab position as of Q1 2024 after selling out during the quarter.
  • Lazard Asset Management sold 879 Genmab shares in Q1 2024, an estimated $27K.
  • Lazard Asset Management first reported a position in Genmab in Q3 2019 and held it in 18 quarters.
  • Lazard Asset Management's Genmab position peaked at $37.5M in Q4 2019.
  • 227 funds tracked by Wall St. Rank held Genmab as of Q1 2024.

Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.